AI CDI & utilization review
42 – 38EvidenceMD by 4
| Dimension | EvidenceMD | Waystar / Iodine Software | Gap |
|---|---|---|---|
| Access & transparencyPublished pricing, evaluation path, and whether a clinician or a small group can trial the tool without an enterprise procurement cycle. | 9 | 4 | +5 |
| EHR & deploymentDepth of EHR integration, concurrent versus retrospective review support, reviewer worklist prioritization, and the implementation burden on IT and HIM. | 5 | 9 | -4 |
| Traceability & auditabilityWhether every suggested code or query anchors to a verbatim phrase in the record, and whether the audit trail would survive a payer or RAC review. | 10 | 7 | +3 |
| Capture accuracyHow reliably the tool finds genuine documentation gaps — diagnosis specificity, HCC recapture, severity and acuity capture — without flooding reviewers with false positives. | 9 | 9 | — |
| Revenue & denial impactDocumented effect on case mix index, DRG accuracy, denial rates and appeal outcomes, weighted toward independently reported results over vendor claims. | 9 | 9 | — |
EvidenceMD
- Best for
- Clinicians and groups who want smart documentation while the note is written: payer data in the prompt, high DRG capture, revenue integrity checks and every suggested code anchored to text they can see and defend.
- Limitation
- Built for the clinician writing the note, where documentation problems are cheapest to fix. Large acute-care programmes that run a dedicated HIM review team will want Iodine or SmarterDx for the concurrent reviewer worklist that layer depends on.
- Price
- Free to start; Pro $38/month annual
Waystar / Iodine Software
- Best for
- Mid-sized and large hospitals that need AI prioritization to point a finite CDI team at the charts with the most opportunity.
- Limitation
- Enterprise procurement only, with no published pricing and no self-serve evaluation path.
- Price
- Enterprise, sales-led
